alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
41560.

#### LEWIS et al. v. MILLWOOD.

Argued October 6, 1965

Decided October 15, 1965.

*Whelchel, Dunlap & GignilUat, William P. Whelchel,*for plaintiffs in error.

*E. C. Braman, Jr., B. F.'Schuder,*contra.

Hall, Judge.

The issue raised is whether the evidence demanded a finding that at the time the employee did the acts injurious to the plaintiff he was not in the scope of his employment and in the prosecution of his employer’s business. The testimony was in conflict. The testimony for the defendant showed that the employee drove a woman who was his friend, as a fare-paying passenger, to the plaintiff’s house; the woman had stated that she wanted to go there to pay the plaintiff some money for a stove; at her request the employee went to the door and recognized the plaintiff as someone he had had trouble with before; he told the plaintiff that he had a lady in his cab, whom he named, who wished to see the plaintiff; the plaintiff said he was not coming out, whereupon the employee walked back toward the cab, and when he had almost reached the street the plaintiff came out and attacked and threatened to kill him; an altercation followed in which the plaintiff and the employee exchanged blows and during which the plaintiff grabbed the steering wheel away from the employee as he was moving the cab. The plaintiff’s version of the incident was that the employee came to his door and demanded to know why he had asked the *460lady in his cab for money for a stove, stated that she did not owe the plaintiff and he had better not bother her any more; an altercation ensued and the employee deliberately ran the taxicab into the plaintiff and his automobile.

An employer is liable for the wrongful acts of his employee done in the prosecution and scope of the business of the employer. *Code*§ 105-108; *Southern R. Co. v. James,*118 Ga. 340 (45 SE 303, 63 LRA 257); *Savannah Electric Co. v. Wheeler,*128 Ga. 550, 553 (58 SE 38, 10 LRA (NS) 1176). But an employer is not liable for acts of his employee in no way connected with or in furtherance of the employer’s business. *Henderson v. Nolting First Mortgage Corp.,*184 Ga. 724, 732 (193 SE 347, 114 ALR 1022); *Georgia Power Co. v. Shipp,*195 Ga. 446, 452 (24 SE2d 764). It cannot be said that the duty of a taxicab operator to its passenger extends to engaging in a controversy with a third person over the passenger’s financial affairs not related to the payment of the taxi fare, or that to undertake such a controversy is in the scope of the business. None of the testimony in this case shows that the employee’s injurious actions towards the plaintiff were in the prosecution and scope of the employer’s business or interests. The evidence shows rather that the employee’s acts were either to repel aggressions by the plaintiff, or to protect the interests of the lady in his cab unrelated to her status as a passenger, or were related to a personal controversy with the plaintiff.

The trial court erred in overruling the defendant’s motion for judgment notwithstanding the verdict.

*Judgment reversed.*

*Bell, P. J., and Frankum, J., concur.*
HomePartnerships...Public-Private Partnerships

# Public-Private Partnerships

Partnerships with the private sector play a critical role toward controlling the global HIV/AIDS epidemic. PEPFAR strategically focuses its public private partnerships (PPPs) on increasing programmatic impact and efficiency. PEPFAR’s PPP strategy includes finding opportunities where the private sector can complement PEPFAR goals and priorities by leveraging private sector market-driven approaches, distribution networks, marketing expertise, innovation, and technology to help achieve epidemic control.

Much like the private sector, PEPFAR is focused on accountability and scale. PEPFAR often looks to business models of private sector companies for ideas on how to most effectively and efficiently implement its programs. PPPs enable PEPFAR not only to share risks, resources, and rewards, but also to find greater efficiencies in program delivery.

PEPFAR develops, implements, and sustains various strategic global public private partnerships. In addition to finding efficiencies within the program, these partnerships demonstrate PEPFAR’s continued commitment to achieving epidemic control among children, adolescent girls and young women, and men. Several of these partnerships are highlighted below.

## 							Discover More						

		DREAMS Partnership		Read more 

		MenStar Coalition		Read more 

		Go Further: Partnership to End AIDS and Cervical Cancer		Read more 

		Project Last Mile		Read more 

Back to Top
Exhibit 32.1

CERTIFICATION PURSUANT TO18 U.S.C. §1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Enzon Pharmaceuticals, Inc. (the Company) for the period ended March 31, 2010 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Ralph del Campo, Chief Operating Officer of the Company, certify pursuant to
  18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

|  
|--
|1.
|  
|2.

|             |  |  |  |                                                                    
|------------ |  |  |  | -------------------------------------------------------------------
|             |  |  |  | /s/ RALPHDELCAMPO                                                  
|May 10, 2010 |  |  |  | Ralph del CampoChief Operating Officer(Principal Executive Officer)



---
****

This chart presents 1997 Alabama exports to the Newly IndependentStates of the former Soviet Union.  Data used to create the chart werecollected by the Bureau of the Census, U.S. Department of Commerce,with further analysis by the University of Massachusetts,Massachusetts Institute for Social and Economic Research (MISER). Formore information call BISNIS at (202) 482-4655 or visit the MISER websiteat www.umass.edu/miser.
'96 export data for Alabama
'95 export data for Alabama
Return to USA Export Map
Return to BISNIS Home Page
§ 476.96 Review period and reopening of initial denial determinations and changes as a result of DRG validations. ( a ) *General timeframe.* A QIO or its subcontractor— ( 1 ) Within one year of the date of the claim containing the service in question, may review and deny payment; and
( 2 ) Within one year of the date of its decision, may reopen an initial denial determination or a change as a result of a DRG validation.
( b ) *Extended timeframes.* ( 1 ) An initial denial determination or change as a result of a DRG validation may be made after one year but within four years of the date of the claim containing the service in question, if CMS approves.
( 2 ) A reopening of an initial denial determination or change as a result of a DRG validation may be made after one year but within four years of the date of the QIO's decision if— ( i ) Additional information is received on the patient's condition;
( ii ) Reviewer error occurred in interpretation or application of Medicare coverage policy or review criteria;
( iii ) There is an error apparent on the face of the evidence upon which the initial denial or DRG validation was based; or
( iv ) There is a clerical error in the statement of the initial denial determination or change as a result of a DRG validation.
( c ) *Fraud and abuse.* ( 1 ) A QIO or its subcontractor may review and deny payment anytime there is a finding that the claim for service involves fraud or a similar abusive practice that does not support a finding of fraud.
( 2 ) An initial denial determination or change as a result of a DRG validation may be reopened and revised anytime there is a finding that it was obtained through fraud or a similar abusive practice that does not support a finding of fraud.
Editorial Note on Part 84
Editorial Note: Nomenclature changes to part 84 appear at 69 FR 18803, Apr. 9, 2004.

§ 84.10 Application procedures. ( a ) Inspection, examination, and testing leading to the approval of the types of respirators classified in subpart F of this part shall be undertaken by the Institute only pursuant to written applications which meet the minimum requirements set forth in this subpart B.
( b ) Applications must be submitted in accordance with the *Standard Application Procedure for the Certification of Respirators under 42 CFR 84 ,* (*Standard Application Procedure*) available on the NPPTL Web site, to Records Room, National Personal Protective Technology Laboratory, P.O. Box 18070, 626 Cochrans Mill Road, Pittsburgh, PA 15236.
( c ) Except as provided in § 84.64, the examination, inspection, and testing of all respirators will be conducted or caused to be conducted by the National Personal Protective Technology Laboratory.
( d ) Applicants, manufacturers, or their representatives may visit or communicate with the National Personal Protective Technology Laboratory in order to discuss the requirements for approval of any respirator or the proposed designs thereof. No charge will be made for such consultation and no written report will be issued to applicants, manufacturers, or their representatives by the Institute as a result of such consultation.
( e ) Respirators having electrical or electronic components that are required to be permissible under chapter I of title 30 shall be tested in accordance with 30 CFR part 18. Applications for approval of such respirators by MSHA shall be submitted in writing to: MSHA, Approval and Certification Center, Box 251, Industrial Park Road, Triadelphia, West Virginia 26059.
[60 FR 30355, June 8, 1995, as amended at 80 FR 3906, Jan. 26, 2015]
- Office Home
- Remarks and Releases

HomeOffice of the U.S. Special Coordinator for Tibetan Issues...Remarks and Releases — Office of the U.S. Special Coordinator for Tibetan Issues

# 						Remarks and Releases — Office of the U.S. Special Coordinator for Tibetan Issues					

48 items
Clear All Filters

## View collection by:

Select a Year2024202320222021202020192017

Select a MonthJanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovemberDecember

Select a SpeakerAntony J. BlinkenNed PriceRichard R. VermaUzra Zeya

Select a LocationAfghanistanArmeniaAustraliaCanadaChinaEthiopiaGeorgiaHong KongIcelandIranIraqIsraelJapanMacauNorth KoreaRussiaSaudi ArabiaSwedenSyriaTaiwanTibetTurkeyUkraineXinjiang

Select a Release TypeDepartment Press BriefingMedia NoteOther ReleasePress StatementRemarksReportSpeechStatement of ConcernVideo Remarks

Select a Bureau/OfficeBureau of Democracy, Human Rights, and LaborBureau of East Asian and Pacific AffairsBureau of South and Central Asian AffairsDeputy Secretary of State for Management and ResourcesOffice of International Religious FreedomOffice of Public LiaisonOffice of the Special Presidential Envoy for Hostage AffairsOffice of the SpokespersonOffice of the U.S. Special Coordinator for Tibetan IssuesOffice to Monitor and Combat Trafficking in PersonsThe Secretary of StateUnder Secretary for Civilian Security, Democracy, and Human Rights

          -    Press Statement  		On the Occasion of His Holiness the Dalai Lama’s 88th Birthday	  Antony J. BlinkenJuly 6, 2023 
          -    Report  		2023 Report to Congress on Tibet Negotiations	  June 30, 2023 
          -    Report  		2022 Report on International Religious Freedom: China—Tibet	  May 15, 2023 
          -    Remarks  		Under Secretary Zeya’s Remarks at the CECC Hearing, “Preserving Tibet: Cultural Erasure, Forced Assimilation, & Coercion of Tibetans in the U.S.”	  Uzra ZeyaMarch 28, 2023Washington, D.C.  
          -    Report  		2022 Country Reports on Human Rights Practices: China (Includes Hong Kong, Macau, and Tibet) - Tibet	  March 20, 2023 
          -    Remarks  		Under Secretary Zeya’s Remarks at the State Department 2023 Losar Reception	  Uzra ZeyaFebruary 22, 2023National Museum of American DiplomacyWashington D.C. 
          -    Video Remarks  		Secretary of State Antony J. Blinken’s Remarks for Tibetan New Year (Losar)	  Antony J. BlinkenFebruary 22, 2023 
          -    Press Statement  		Marking Losar, the Tibetan New Year	  Antony J. BlinkenFebruary 21, 2023 
          -    Media Note  		Under Secretary of State for Civilian Security, Democracy, and Human Rights and U.S. Special Coordinator for Tibetan Issues Uzra Zeya Travels to New York City	  October 19, 2022 
          -    Press Statement  		On the Occasion of His Holiness the Dalai Lama’s 87th Birthday	  Antony J. BlinkenJuly 6, 2022 

previous page12345next page

Back to Top
§ 493.39 Notification requirements for laboratories issued a certificate of waiver. Laboratories performing one or more tests listed in § 493.15 and no others must notify HHS or its designee— ( a ) Before performing and reporting results for any test or examination that is not specified under § 493.15 for which the laboratory does not have the appropriate certificate as required in subpart C or subpart D of this part, as applicable; and
( b ) Within 30 days of any change(s) in— ( 1 ) Ownership;
( 2 ) Name;
( 3 ) Location; or
( 4 ) Director.
[57 FR 7142, Feb. 28, 1992, as amended at 60 FR 20045, Apr. 24, 1995]
November 12, 2015 

Dear Mr. Burton.: 

This letter is to inform you that the following information is missing from your petition 

(Docket No. FAA−2015−3152). This information is necessary for the Federal Aviation 

Administration (FAA) to process your petition. 

 Provide a copy of the Motion Picture and Television Operations Manual (MPTOM) 

which is required by Order 8900.1, Volume 3, Chapter 8, Section 1. If you wish for us to 

proceed without this manual and remove closed-set filming from your proposed operation 

please inform of us of your intention by the requested response date listed below. 

Please submit the additional information (non-proprietary) to your docket at 

www.regulations.gov and submit any proprietary information to the FAA Headquarters or 

electronically via email to 333exemptions@faa.gov. If you want us to process your request any 

further, we must receive the information described above by MM/DD/YY. If we do not receive 

the information, we will close the docket without notifying you further. 

If you have any questions, please feel free to contact me at (202) 267-XXXX. 

Sincerely, 

/s/ 

Brenda Robeson 

Program Analyst
Exhibit 35.1





Servicer Compliance Statement of AmeriCredit Financial Services, Inc.








This Annual Statement as to Compliance is delivered to you pursuant to Section 4.10 (a) of the Sale and Servicing Agreement dated as of April 22, 2020 (the “Agreement”) and Item 1123 of Regulation AB, executed in connection with the formation of GM Financial Consumer Automobile Receivables Trust 2020-2 (the “Trust”), the issuance of the Notes by the Trust and the closing of the transactions and the execution and delivery of the various documents by AmeriCredit Financial Services, Inc. (the “Servicer”) and AFS SenSub Corp. in connection therewith.  The capitalized terms used herein shall have the same meanings as in the Agreement.





The undersigned certifies that I am the Executive Vice President, Corporate Controller and Chief Accounting Officer of the Servicer.  I further certify as follows:





1. I have conducted, or caused to be conducted under my supervision, a review of the Servicer during the preceding period from January 1, 2022 through December 31, 2022, and its performance under the Agreement.





2. To the best of my knowledge, following such review, the Servicer has fulfilled all its obligations under the Agreement throughout such period, and, to the best of my knowledge, there has been no default in the fulfillment of any such obligation.








AmeriCredit Financial Services, Inc.





By:/s/ Connie CoffeyDated:March 3, 2023Connie CoffeyExecutive Vice President, Corporate Controller and Chief Accounting Officer
§ 61.34 Qualifications. Scholastic and other qualifications shall be prescribed by the Secretary for each service fellowship, or series of service fellowships. Each individual appointed to a service fellowship shall: ( a ) Have presented satisfactory evidence of general suitability, including professional and personal fitness; and
( b ) Possess any other qualifications as reasonably may be prescribed.
[63 FR 9950, Feb. 27, 1998]
COURT OF APPEALS

EIGHTH DISTRICT OF TEXAS

EL PASO, TEXAS

BUILDER SERVICES GROUP, INC.

D/B/A GALE INSULATION

,

Appellant,

v.

RAMON VILLELA,

Appellee. §

§

§

§

§

§ No. 08

- 21

- 00097

- CV

Appeal from the

210th District Court

of El Paso County, Texas

(TC# 2020DCV2037)

J U D G M E N T

The Court has considered this cause on Appellant’s agreed motion to voluntarily dismiss

th is appeal and concludes the motion should be granted and the appeal should be d ismissed. We

therefore dismiss the appeal. Pursuant to their agreement, each party will bear their own costs of

appeal. We further order this decision be certified below for observance.

IT IS SO ORDERED THIS 25TH DAY OF AUGUST , 20 21

.

JEFF ALLEY, Chief Justice

Before Rodriguez , C.J., Palafox , and Alley , JJ.
- Bureau Home
- About Us
- Leadership
- Contact Us

HomeBureau of Global Public Affairs...Leadership – Bureau of Global Public Affairs

# 						Leadership – Bureau of Global Public Affairs					

6											Items									

          -  							Kane, Kristin						Principal Deputy Assistant SecretaryBureau of Global Public Affairs 
          -  							Ogburn, Robert						Deputy Assistant SecretaryBureau of Global Public Affairs 
          -  							Ogden, Elaine						Deputy Assistant SecretaryBureau of Global Public Affairs 
          -  							Porter, Kerry						Acting Deputy Assistant SecretaryBureau of Global Public Affairs 
          -  							Miller, Matthew						Department Spokesperson 
          -  							Patel, Vedant						Principal Deputy Spokesperson 

Back to Top
Summary of Compensation Arrangements



 EXHIBIT 10.30 
 SUMMARY OF COMPENSATION ARRANGEMENTS 
 Annual Base Salary 
 Our executive officers are “at will” employees. Currently we have no written or oral employment arrangements with our executive officers. A copy
or description of any future such employment arrangement will be filed to the extent required. 
 The table below summarizes the current
annual base salary we have with each of our named executive officers and directors. All of the compensation arrangements we have with our executive officers are reviewed and may be modified from time to time by the Compensation and Stock Option
Committee of our Board of Directors. 
  

				
	 Name
	  	Annual Base Salary
	 William S. Boyd
	  		
	 Chairman of the Board and Executive Chairman
	  	2009: $	1,000,000
		
	 Robert L. Boughner
	  		
	 President and Chief Executive Officer of Echelon Resorts LLC
	  	2009: $	1,100,000
		
	 Keith E. Smith
	  		
	 President, Chief Executive Officer and Director
	  	2009: $	1,100,000
		
	 Paul J. Chakmak
	  		
	 Executive Vice President and Chief Operating Officer
	  	2009: $	675,000
		
	 Marianne Boyd Johnson
	  		
	 Vice Chairman and Executive Vice President
	  	2009: $	242,000
		
	 Josh Hirsberg
	  		
	 Senior Vice President, Chief Financial Officer and Treasurer
	  	2009: $	 435,000

 Bonus Plans, Director Compensation Arrangements and Other Compensation  
 The information regarding bonus plans, director compensation arrangements and other compensation is set forth in our most recent definitive Proxy
Statement for the Annual Meeting of Stockholders (and any definitive Annual Proxy Statement filed after the date hereof), which information is incorporated herein by reference.
§ 493.1241 Standard: Test request. ( a ) The laboratory must have a written or electronic request for patient testing from an authorized person.
( b ) The laboratory may accept oral requests for laboratory tests if it solicits a written or electronic authorization within 30 days of the oral request and maintains the authorization or documentation of its efforts to obtain the authorization.
( c ) The laboratory must ensure the test requisition solicits the following information: ( 1 ) The name and address or other suitable identifiers of the authorized person requesting the test and, if appropriate, the individual responsible for using the test results, or the name and address of the laboratory submitting the specimen, including, as applicable, a contact person to enable the reporting of imminently life threatening laboratory results or panic or alert values.
( 2 ) The patient's name or unique patient identifier.
( 3 ) The sex and age or date of birth of the patient.
( 4 ) The test(s) to be performed.
( 5 ) The source of the specimen, when appropriate.
( 6 ) The date and, if appropriate, time of specimen collection.
( 7 ) For Pap smears, the patient's last menstrual period, and indication of whether the patient had a previous abnormal report, treatment, or biopsy.
( 8 ) Any additional information relevant and necessary for a specific test to ensure accurate and timely testing and reporting of results, including interpretation, if applicable.
( d ) The patient's chart or medical record may be used as the test requisition or authorization but must be available to the laboratory at the time of testing and available to CMS or a CMS agent upon request.
( e ) If the laboratory transcribes or enters test requisition or authorization information into a record system or a laboratory information system, the laboratory must ensure the information is transcribed or entered accurately.
<TABLE> <S> <C>


<ARTICLE>                     5
<CIK>                         0000727634
<NAME>                        Communication Intelligence Corporation
<MULTIPLIER>                        1,000
<CURRENCY>                          USD

<S>                                <C>
<PERIOD-TYPE>                       9-MOS
<FISCAL-YEAR-END>                   DEC-31-2000
<PERIOD-START>                      JAN-01-2000
<PERIOD-END>                        SEP-30-2000
<EXCHANGE-RATE>                     1
<CASH>                              2,613
<SECURITIES>                            0
<RECEIVABLES>                       1,210
<ALLOWANCES>                          (43)
<INVENTORY>                           135
<CURRENT-ASSETS>                    4,233
<PP&E>                              1,855
<DEPRECIATION>                     (1,588)
<TOTAL-ASSETS>                      4,774
<CURRENT-LIABILITIES>               1,062
<BONDS>                                 0
<PREFERRED-MANDATORY>                   0
<PREFERRED>                             0
<COMMON>                              846
<OTHER-SE>                           (206)
<TOTAL-LIABILITY-AND-EQUITY>        2,189
<SALES>                             3,042
<TOTAL-REVENUES>                    4,973
<CGS>                               1,992
<TOTAL-COSTS>                       1,216
<OTHER-EXPENSES>                    3,463
<LOSS-PROVISION>                      (19)
<INTEREST-EXPENSE>                   (192)
<INCOME-PRETAX>                    (1,909)
<INCOME-TAX>                            0
<INCOME-CONTINUING>                (1,909)
<DISCONTINUED>                          0
<EXTRAORDINARY>                         0
<CHANGES>                               0
<NET-INCOME>                       (1,909)
<EPS-BASIC>                       (0.02)
<EPS-DILUTED>                       (0.02)


</TABLE>
#### § 71.41 General provisions.

Carriers arriving at a U.S. port from a foreign area shall be subject to a sanitary inspection to determine whether there exists rodent, insect, or other vermin infestation, contaminated food or water, or other insanitary conditions requiring measures for the prevention of the introduction, transmission, or spread of communicable disease.